CMO Dawn Keller explains why a social-first approach is required for a brand that doesn’t have a massive advertising budget.

The US regulator has cleared the combination of muscarinic M1 and M4 agonist xanomeline tartrate and muscarinic antagonist trospium chloride ... under the Cobenfy brand name for the treatment ...

A brand new biotech – Neurosterix – has been ... this year on its schizophrenia candidate KarXT (xanomeline tartrate/trospium chloride), which combines an M4 antagonist with an M1 agonist ...